Generic Name and Formulations:
Quinine sulfate 324mg; caps.
Sun Pharmaceutical Industries
Indications for QUALAQUIN:
Treatment of uncomplicated P. falciparum malaria (including chloroquine-resistant strains).
Take with food. ≥16yrs: 648mg every 8hrs for 7 days. Severe renal impairment: 648mg once, after 12hrs start 324mg every 12hrs. Hepatic impairment (severe): not recommended; (mild and moderate): monitor closely.
<16yrs: not established.
Prolonged QT interval. G6PD deficiency. Myasthenia gravis. Mefloquine, quinidine or related allergy. History of thrombocytopenic purpura, hemolytic uremic syndrome, thrombocytopenia, blackwater fever associated with previous quinine use. Optic neuritis.
Not for treatment of severe or complicated P. falciparum malaria. Not for prevention of malaria. Not for treatment or prevention of nocturnal leg cramps; serious and life-threatening hematologic reactions may develop. Discontinue if any signs/symptoms of hypersensitivity occurs (eg, thrombocytopenic purpura, hemolytic uremic syndrome, thrombocytopenia, blackwater fever). Underlying structural heart disease. Preexisting conduction abormalities. Cardiac arrhythmias. Atrial fibrillation or atrial flutter. MI. Hypoglycemia. Hypokalemia. Bradycardia. Severe hepatic impairment: use alternative therapy. Elderly with sick sinus syndrome. Pregnancy (Cat.C). Nursing mothers.
Quinoline (cinchona alkaloids).
Avoid drugs that can prolong QT interval (eg, quinidine, procainamide, disopyramide, amiodarone, sotalol, dofetilide), other CYP3A4 substrates (eg, cisapride, terfenadine, pimozide, halofantrine, quinidine), erythromycin, troleandomycin. Avoid concomitant mefloquine, halofantrine (may cause seizures or ECG changes), rifampin, ritonavir, antacids. Potentiates warfarin, oral anticoagulants, neuromuscular blocking agents (avoid). Potentiated by urinary alkalizers. May potentiate atorvastatin (monitor). May antagonize anticonvulsants (eg, carbamazepine, phenobarbital, phenytoin), CYP2D6 substrates (eg, flecainide, metoprolol, paroxetine, dextromethorphan). Increases digoxin levels (monitor). Monitor cimetidine, ranitidine, ketoconazole, tetracycline, theophylline, aminophylline.
Headache, vasodilation, sweating, nausea, tinnitus, hearing impairment, vertigo, dizziness, blurred vision, disturbances in color perception, cardiac rhythm or conduction, vomiting, diarrhea, abdominal pain, deafness, blindness, lupus-like syndrome, blood dyscrasias; rashes (may be serious, eg, Stevens-Johnson), cardiovascular effects (eg, chest pain, AV block, torsades de pointes), hypoglycemia (esp. in pregnancy).
Caps—30, 100, 500, 1000
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Cognitive Behavioral Therapy May Alter Suicidal Ideation in Anxiety Disorders
- Text Message Reminders Improve Medication Adherence in Bipolar I Disorder
- Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in Adulthood
- High Suicidality Among Children With ADHD Mediated by Family Functioning, Psychiatry Comorbidities
- Pilot Study Investigates Lithium vs Quetiapine for Bipolar Spectrum Disorder
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age